Dermatology
Conference Coverage
Psoriasis associated with an increased risk of COVID-19 in real-world study
Those treated with TNF-alpha inhibitors, methotrexate, and apremilast had statistically lower risks of COVID-19 vs. those on topical therapy.
News
Study aims to enhance understanding of ‘tremendously understudied’ prurigo nodularis
“If you encounter a patient with prurigo nodularis, it’s important to perform a screening for chronic kidney disease, diabetes, and liver disease...
News
Data about COVID-19-related skin manifestations in children continue to emerge
Of 50 hospitalized children infected with COVID-19, 18 (36%) fulfilled criteria for Multisystem Inflammatory Syndrome in Children.
News
Secukinumab brings high PASI 75 results in 6- to 17-year-olds with psoriasis
The week-24 PASI 75 rate was 95% in a phase 2 study.
Conference Coverage
What’s the future of telehealth? It’s ‘complicated’
“The problems are systemic, and they have to do with various factors: The portal, the equipment, Internet access, and inadequate or no health...
News
Researchers stress importance of second COVID-19 vaccine dose for infliximab users
Significantly lower antibody concentrations seen after a first dose of the Pfizer or AstraZeneca vaccine in users of infliximab vs. vedolizumab...
Conference Coverage
National Psoriasis Foundation recommends some stop methotrexate for 2 weeks after J&J vaccine
The rationale is to optimize the antibody response to the killed-adenovirus COVID-19 vaccine.
Conference Coverage
Severe atopic dermatitis often puts a dent in quality of life
“There have been many surveys of adults with AD who report impairment of their sleep, reduced activity level, increased work absence, financial...
Conference Coverage
Pandemic puts patients with psoriatic disease off seeking medical help
Both the physical and mental health of people with psoriasis and psoriatic arthritis has been affected by the ongoing COVID-19 pandemic.
Conference Coverage
International expert group agrees on redefining psoriasis severity
“What we came up with is a very sensible approach to defining whether patients should get either topical or systemic therapy.”